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The first angiotensin II (AngII) type 1 receptor 
(AT1R) blocker (ARB) or sartan (short for 
Angiotensin-RecepTor-ANtagonist) approved by 
the United States Food and Drug Administration 
(FDA) for hypertension was losartan in the 1990s, 
rapidly followed by candesartan, eprosartan, irbe-
sartan, valsartan, telmisartan, and olmesartan. The 
ARBs bind the AT1R with high affinity.1 ARBs 
were developed to complement the efficacy of 
angiotensin converting enzyme inhibitors (ACEIs) 
and to also do away with the major adverse effects 
of the latter drug class, that is, dry cough, thought 
to result from elevation of proneuro-inflammatory 
bradykinin levels in the lungs (ACE activates brad-
ykinin from precursor kinins and the vast lung 
endothelium is particularly rich in this enzyme), 
and angioedema (also kinin-dependent).2 ACEIs 
do not completely abrogate AngII production in 
the body, as synthesis of this peptide hormone can 
occur via alternative enzymatic pathways, such as 
chymase and other tissue-based proteases.3 These 
alternative pathways can become upregulated 
upon long-term ACEI use, resulting in reduced 
antihypertensive efficacy. The hemodynamic 
effects of ARBs are similar to those of ACEIs. 
Because AngII is a very potent vasoconstrictor 
 peptide (second most potent endogenous 
The place of ARBs in heart failure therapy: is 
aldosterone suppression the key?
Uma Markan, Samhitha Pasupuleti, Celina M. Pollard, Arianna Perez,  
Beatrix Aukszi and Anastasios Lymperopoulos
Abstract: Since the launch of the first orally available angiotensin II (AngII) type 1 receptor 
(AT1R) blocker (ARB) losartan (Cozaar) in the late 1990s, the class of ARBs (or ‘sartans’, 
short for Angiotensin-RecepTor-ANtagonistS) quickly expanded to include candesartan, 
eprosartan, irbesartan, valsartan, telmisartan, and olmesartan. All ARBs have high affinity for 
the AT1 receptor, expressed in various tissues, including smooth muscle cells, heart, kidney, 
and brain. Since activation of AT1R, the target of these drugs, leads, among other effects, to 
vascular smooth muscle cell growth, proliferation and contraction, activation of fibroblasts, 
cardiac hypertrophy, aldosterone secretion from the adrenal cortex, thirst-fluid intake 
(hypervolemia), etc., the ARBs are nowadays one of the most useful cardiovascular drug 
classes used in clinical practice. However, significant differences in their pharmacological 
and clinical properties exist that may favor use of particular agents over others within the 
class, and, in fact, two of these drugs, candesartan and valsartan, continuously appear to 
distinguish themselves from the rest of the ‘pack’ in recent clinical trials. The reason(s) for the 
potential superiority of these two agents within the ARB class are currently unclear but under 
intense investigation. The present short review gives an overview of the clinical properties 
of the ARBs currently approved by the United States Food and Drug Administration, with a 
particular focus on candesartan and valsartan and the areas where these two drugs seem 
to have a therapeutic edge. In the second part of our review, we outline recent data from our 
laboratory (mainly) on the molecular effects of the ARB drugs on aldosterone production and 
on circulating aldosterone levels, which may underlie (at least in part) the apparent clinical 
superiority of candesartan (and valsartan) over most other ARBs currently in clinical use.
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vasoconstrictor hormone behind endothelin), AT1R 
blockade leads to vasodilation and reduction in 
total peripheral resistance (i.e. cardiac afterload) 
and blood pressure lowering.4 Cardiac output 
remains unchanged. Despite BP lowering, heart 
rate remains unchanged, and there is no postural 
hypotension, likely because ARBs reset barorecep-
tor function.4
Like ACEIs, ARBs are able to protect target 
organs in hypertensive patients. Indeed, long-
term administration of ARBs reduces left ventric-
ular hypertrophy, improves endothelial function, 
induces destiffening of large arteries and reverse 
remodeling of large and small arteries.5–7 
Relaxation of large arteries leads to lowering of 
central systolic and pulse pressures.8 Renal pro-
tection is observed in early diabetic nephropathy, 
and proteinuria is reduced independently of the 
hypotensive effect.9,10 ARBs are contrandicated in 
pregnancy, in the presence of hyperkalemia, and 
in bilateral renal artery stenosis.11 ARBs differ in 
their AT1R binding kinetics. Candesartan is 
known to confer insurmountable (noncompteti-
tive) antagonism at the receptor thanks to the 
 carboxyl group attached to its benzimidazole 
side-chain (Figure 1).12 However, telmisartan, 
which lacks this carboxyl moiety, and valsartan, 
which has it but lacks the benzimidazole ring, also 
exhibit noncompetitive antagonism of the AT1R 
(Figure 1).12 In addition, candesartan and valsar-
tan are known to stabilize the AT1R in its inactive 
conformation, that is, they are, in essence, inverse 
agonists.10–13 All ARBs in clinical use are 
>10,000-fold selective for the AT1R versus AT2R, 
with candesartan being among the most AT1R-
selective agents.13–16
Clinical comparison of ARB agents
In a meta-analysis of 14 studies, comprising 8 on 
hypertensive patients and 6 on heart failure (HF) 
patients, candesartan was found to induce a 
(albeit slightly) greater extent of blood pressure 
reduction compared with losartan.17 Nevertheless, 
this difference was deemed unlikely to be cost 
effective. In HF patients, both ARBs were found 
more or less equieffective at symptomatic 
improvement.18 In one study, however, cande-
sartan was found superior to losartan in terms of 
mortality and hospitalization rate reductions, 
although the fact that the losartan might have 
been underdosed in the patients of this study 
casts doubt on its conclusions.19 Unfortunately, 
clinical head-to-head comparisons between other 
ARB agents, or between candesartan or losartan 
versus any other ARB agent, are still lacking.
An interesting new angle on the therapeutic effi-
cacy of ARBs for HF was provided recently with 
Figure 1. Chemical structures of the individual angiotensin II (AngII) type 1 receptor (AT1R) blockers (ARBs) 
discussed extensively in the present review.
U Markan, S Pasupuleti et al.
http://tac.sagepub.com 3
the approval and market entry of Novartis’s 
Entresto® (sacubitril/valsartan), the first first-
in-class drug to be approved by the FDA for HF 
treatment in more than two decades.20–23 In this 
drug, the potent ARB valsartan is combined 
with sacubitril, which is a neprilysin (NEP) 
inhibitor. NEP is a neutral endopeptidase that 
degrades natriuretic peptides and other vasodi-
lating peptides, for example, substance P and 
bradykinin, as well as vasoconstricting peptides, 
for example, endothelin and AngII.24 In fact, 
exactly because NEP inhibition can increase 
AngII levels, sacubitril and all NEP inhibitors 
have to be combined with an ARB for HF treat-
ment.24 The 1:1 stoichiometric combination of 
sacubitril and valsartan was shown to confer 
additional clinical benefit in HF with reduced 
ejection fraction (HFrEF) patients on top of 
their standard treatment. Importantly, NEP 
inhibition with sacubitril seems to provide clini-
cal benefits that valsartan (Diovan) alone can-
not, including reduction in the left atrial size, 
reverse left atrial remodeling, and New York 
Heart Association (NYHA) class improve-
ment.21,23 In the PARADIGM trial, which piv-
oted Entresto® into regulatory approval in the 
US and in Europe, sacubitril/valsartan con-
ferred benefits for HFrEF patients, significantly 
reducing morbidity and mortality compared 
with enalapril.21 The molecular mechanisms 
underlying the additional clinical benefits of 
NEP inhibition when added to the ARB valsar-
tan are presently unknown. Interestingly, how-
ever, modulation of aldosterone levels (see 
below) might be a major part of this mechanism, 
since natriuretic peptides inhibit aldosterone 
secretion from the adrenal cortex, which means 
that NEP promotes it while degrading AngII, 
the major physiological stimulus for adrenal 
aldosterone secretion (again, see below), at the 
same time.25–28 It is thus plausible that an ARB 
(e.g. valsartan) alone is insufficient to fully sup-
press aldosterone in HFrEF, due to elevated 
overall (and obesity-specific) NEP activity, and 
the addition of a NEP inhibitor (such as sacubi-
tril in Entresto®) helps produce the additional 
aldosterone suppression necessary to confer 
substantial clinical benefits in human HFrEF. 
In other words, the degree of adrenal-derived 
aldosterone suppression may hold the mecha-
nistic key to Entresto®’s clearly demonstrated 
clinical benefits in HF. This, of course, remains 
to be validated in clinical trials of HF patients 
treated with Entresto® and assessing/comparing 
their circulating aldosterone levels versus 
patients treated with valsartan (or some other 
ARB) without a NEP inhibitor.
Effects of ARBs on aldosterone production
AngII, alongside hyperkalemia, is the most 
 powerful physiological stimulus for adrenocorti-
cal aldosterone synthesis and secretion. This 
effect is mediated by the adrenocortical AT1R, 
which is a G protein-coupled receptor (GPCR) 
that can signal to aldosterone production via two 
independent pathways: a well-established G 
 protein-dependent pathway, via generation of the 
second messengers diacylglycerol and inositol 
 trisphosphate, which ultimately upregulate StAR 
(steroidogenic acute regulatory) protein, and 
β-arrestin-1 (also known as Arrestin-2), which 
also can upregulate StAR in the adrenal cortex via 
ERK activation (Figure 2).29,30 Full blockade 
of both pathways is required to suppress 
adrenal aldosterone production completely.31,32 
Interestingly, several ARBs have been reported to 
be ineffective at lowering aldosterone in HF, 
despite completely blocking the AT1R-G protein 
interaction.33–38 This has prompted recent screen-
ings of ARB efficacies at inhibiting the β-arrestin-
1-dependent aldosterone production. Losartan 
was found largely ineffective at blocking β-
arrestin-1-dependent aldosterone production and 
at combatting hyperaldosteronism in animal 
models of HF due to very weak adrenal β-
arrestin-1 inhibition.30,39 In contrast, losartan’s 
active metabolite (EXP1374) was an effective 
suppressor of β-arrestin-1-dependent aldoster-
one.39 Regarding the rest of the currently FDA-
approved ARBs, candesartan and valsartan were 
found the most potent blockers of adrenal β-
arrestin-1-dependent aldosterone both in vitro 
and in vivo (Figure 2).39,40 Conversely, irbesartan, 
similarly to losartan, was a very weak β-arrestin-1 
inhibitor, and, thus, ineffective at suppressing 
aldosterone, despite its excellent G protein-inhib-
itory activity (Figure 2).39,40 Importantly, the 
effects of these ARBs on cardiac function of HF 
animals in vivo followed closely their effects on 
circulating aldosterone levels, that is, candesartan 
and valsartan induced significant improvements 
in cardiac function and adverse remodeling, 
whereas irbesartan and losartan were unable to 
halt progression of myocardial infarction to full-
blown HF in rats.40
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Although virtually next to nothing is known about 
the structural requirements for β-arrestin agonism 
or inverse agonism, it is interesting to point out that 
both of the weak β-arrestin-1-dependent aldoster-
one inhibitors irbesartan and losartan lack the 
 side-carboxyl group present in the potent 
β-arrestin-1-dependent aldosterone inhibitors can-
desartan and valsartan (Figure 1). Moreover, 
EXP1374, losartan’s active metabolite that potently 
inhibits β-arrestin-1-dependent aldosterone,39 also 
has this carboxyl moiety. It is thus tempting to 
speculate that carrying a second negative charge (in 
addition to the indispensable tetrazole ring that 
mimics the Phe8 C-terminus of AngII) is essential 
not only for binding the orthosteric site of AT1R, 
thereby sterically blocking receptor interaction with 
AngII,41 but also potentially for β-arrestin inverse 
agonism. The stereochemical space (‘bulkiness’) 
occupied by the side moieties has to be taken into 
account as well; for instance, a recent study dem-
onstrated the effect of the bulkiness of the Ile5 side-
chain in AngII on β-arrestin agonism at the AT1R.42
In conclusion, based on the above, the ARBs that 
suppress aldosterone (including adrenal β-arrestin-
1-dependent aldosterone) most effectively (e.g. 
candesartan, valsartan) might work better for HF 
therapy. In contrast, irbesartan and losartan, both 
weak adrenal β-arrestin-1-dependent aldosterone 
inhibitors, might be therapeutically inferior for 
clinical HFrEF in terms of morbidity/mortality 
reduction.43–45 Of course, data on serum aldoster-
one levels of ARB-treated HF patients are required 
to confirm or refute this mechanistically derived 
pharmacological rationale. Moreover, the degree 
of adrenal β-arrestin-1-dependent aldosterone 
inhibition conferred by each individual ARB drug 
might have a bearing on the ‘aldosterone break-
through’ or ‘aldosterone escape’ phenomenon, 
which basically describes the long-term failure to 
suppress circulating aldosterone.36–38 In other 
words, the more potent adrenal β-arrestin-1-
dependent aldosterone suppression an ARB 
induces, the less its propensity for ‘aldosterone 
breakthrough’ manifestation. Indeed, there is 
already some experimental evidence pointing to 
adrenal β-arrestin-1 as a possible culprit for the 
‘aldosterone breakthrough’ or ‘aldosterone escape’ 
phenomenon observed with ARBs: a decade-old 
study on candesartan-dependent suppression of 
AngII-induced aldosterone secretion in human 
adrenocortical cells in vitro suggested that bone 
morphogenetic protein (BMP)-6 mediates the 
resistance of these cells to candesartan’s hypoaldo-
steronic actions.46 Since β-arrestins are known to 
enhance BMP signaling in various cell types,47 it is 
Figure 2. The two components of adrenocortical aldosterone production and the degree of their inhibition by 
ARBs.
AT1R, Angiotensin II type 1 receptor; βarr1, β-arrestin-1; G prt, G protein; pERK, phospho-extracellular signal-regulated 
kinase; StAR, Steroidogenic Acute Regulatory protein. The solid black inhibition sign denotes potent inhibition. The dashed 
black inhibition sign denotes weak inhibition.
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quite plausible that adrenal β-arrestin-1 activation 
by the AT1R promotes AngII’s pro-aldosteronic 
effects and the adrenocortical cell’s refractoriness 
to AT1R blockade (with an ARB) over time, that 
is, the ARB-associated ‘aldosterone breakthrough.’ 
The potential role of adrenal βarrestin1 in the 
development of the ARB-associated ‘aldosterone 
breakthrough’ phenomenon definitely warrants 
further investigation in the future.
Conclusion/future perspectives
It is now clear that not all ARBs are clinically or 
pharmacologically equivalent. Thus, neither are 
they therapeutically equal, especially when the 
treatment of a very complex syndrome such as 
HF is considered. Unfortunately, studies com-
paring them head-to-head are very scarce and 
inconclusive. Based on the very limited data avail-
able as of now, certain agents (candesartan, vals-
artan) seem to stand out from their class both 
clinically and pharmacologically. In the present 
review, we have presented some molecular evi-
dence for why these two ARBs in particular might 
be superior over others in the same class: the rea-
son may lie in the degree of adrenal aldosterone 
suppression, and, more specifically, in the extent 
of inhibition of the adrenal β-arrestin-1 compo-
nent of aldosterone production. The level of 
aldosterone suppression afforded may even hold 
the key to the apparent therapeutic success of the 
sacubitril/valsartan combination recently intro-
duced into clinical practice. This hypothesis is 
definitely worth investigating in the future. Of 
course, there is currently no clinical evidence that 
ARBs are superior to ACE inhibitors for patients 
with HFrEF, and more comprehensive prospec-
tive comparative head-to-head trials of the ARBs 
to evaluate their relative efficacy at preventing 
aldosterone escape or breakthrough are definitely 
warranted. However, given the complex hormo-
nal interplay underlying HF pathophysiology, in 
which AngII and aldosterone play prominent 
roles, the fields of ARB pharmacology, and, more 
broadly, of the renin-angiotensin-aldosterone sys-
tem, are bound to keep HF specialists and cardio-
vascular scientists alike on edge for new discoveries 
and therapeutic advances for many years to come.
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